GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunho Biologics Inc (HKSE:02898) » Definitions » 3-Year Dividend Growth Rate

Sunho Biologics (HKSE:02898) 3-Year Dividend Growth Rate : 0.00% (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Sunho Biologics 3-Year Dividend Growth Rate?

Sunho Biologics's Dividends per Share for the six months ended in Dec. 2024 was HK$0.00.

The historical rank and industry rank for Sunho Biologics's 3-Year Dividend Growth Rate or its related term are showing as below:

HKSE:02898's 3-Year Dividend Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 8.95
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Sunho Biologics's Dividend Payout Ratio for the six months ended in Dec. 2024 was 0.00. As of today, Sunho Biologics's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of Sunho Biologics's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, Sunho Biologics's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunho Biologics's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunho Biologics's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Sunho Biologics's 3-Year Dividend Growth Rate falls into.


;
;

Sunho Biologics 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.


Sunho Biologics  (HKSE:02898) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Sunho Biologics's Dividend Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Dec. 2024 )/ EPS without NRI (Q: Dec. 2024 )
=0/ -0.272
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sunho Biologics 3-Year Dividend Growth Rate Related Terms>


Sunho Biologics Business Description

Traded in Other Exchanges
N/A
Address
No. 198 Peninsula Middle Road, Dipu Street, Room 302, Building 3, Anji County, Zhejiang Province, Huzhou, CHN
Sunho Biologics Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases. It has three Core Products, IAH0968, IAP0971, and IAE0972, all of which are developed in-house. IAH0968 is an antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced monoclonal antibody (mAb), and the company has initiated Phase II clinical trials for biliary tract carcinoma (BTC) and colorectal cancer (CRC). IAP0971 and IAE0972 are both immunocytokines and It has completed Phase I clinical trials for advanced solid tumors including non-small cell lung cancer (NSCLC) and CRC.
Executives
Sunho Fortune Investments Limited 2201 Interest of corporation controlled by you
Trident Trust Company (hk) Limited 2301 Trustee
Zhang Feng 2201 Interest of corporation controlled by you
Sunho Wisdom Investments Limited 2101 Beneficial owner

Sunho Biologics Headlines

No Headlines